Daily Endocrinology Research Analysis
Analyzed 108 papers and selected 3 impactful papers.
Summary
The strongest endocrinology findings today include a multicenter randomized trial showing that perioperative dapagliflozin markedly reduced acute kidney injury after elective cardiac surgery, a large multi-ancestry genome-wide association study identifying extensive genetic architecture for Hashimoto's thyroiditis, and a UK Biobank analysis demonstrating that clinical obesity can identify substantial cardiometabolic risk even when BMI is not in the obese range. Together, these studies advance both therapeutic decision-making and disease classification beyond conventional glycemic, anthropometric, and ancestry-limited frameworks.
Research Themes
- Perioperative metabolic and renal protection
- Genetic architecture of autoimmune thyroid disease
- Clinical obesity and risk stratification beyond BMI
Selected Articles
1. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
In this multicenter, double-blind randomized trial of 784 adults undergoing elective cardiac surgery, four perioperative doses of dapagliflozin reduced 7-day postoperative AKI from 52% with placebo to 28% with treatment. The relative risk was 0.54, with no difference in atrial fibrillation or reoperation rates between groups.
Impact: This is a large, rigorously conducted randomized trial addressing a common and clinically important complication for which preventive pharmacotherapy has been lacking. The magnitude of benefit could influence perioperative kidney-protection strategies if confirmed in additional settings and safety studies.
Clinical Implications: A short perioperative course of dapagliflozin may become a candidate strategy for preventing AKI after elective cardiac surgery. Before routine adoption, clinicians should consider confirmation in broader surgical populations and monitor for volume depletion, ketoacidosis, infection, and perioperative medication-management issues.
Key Findings
- AKI occurred in 28% of patients receiving dapagliflozin versus 52% receiving placebo over 7 days.
- The relative risk of postoperative AKI was 0.54 with dapagliflozin, with a 95% confidence interval of 0.45-0.65 and P<0.001.
- Atrial fibrillation occurred in 45% of both groups, and reoperation occurred in 11% versus 10% of the dapagliflozin and placebo groups, respectively.
Methodological Strengths
- Multicenter, double-blind, placebo-controlled randomized clinical trial with 784 enrolled participants and 99% completion of follow-up.
- Prespecified objective AKI definition based on Kidney Disease: Improving Global Outcomes criteria and prospective trial registration.
Limitations
- The study was conducted in elective cardiac surgery patients in the Netherlands, which may limit generalizability to emergency surgery, other procedures, and more diverse populations.
- Follow-up focused on the first 7 postoperative days, so effects on persistent kidney dysfunction, long-term renal outcomes, and mortality were not established.
Future Directions: Future trials should evaluate long-term renal and cardiovascular outcomes, perioperative safety in patients with reduced kidney function or higher ketoacidosis risk, and effectiveness across different cardiac and noncardiac surgical populations.
IMPORTANCE: Two percent to 50% of patients undergoing elective cardiac surgery experience acute kidney injury (AKI) postoperatively. Medications to prevent AKI after elective cardiac surgery have not been identified. OBJECTIVE: In patients undergoing elective cardiac surgery, to evaluate whether initiating dapagliflozin 1 day prior to surgery reduces the incidence of AKI at 7 days after cardiac surgery, compared with placebo. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled randomized clinical trial conducted at 2 academic medical centers and 5 nonacademic hospitals in the Netherlands. Eligible participants were adults undergoing elective cardiac surgery. Enrollment occurred between June 8, 2023, and January 27, 2025. Final follow-up occurred May 16, 2025. INTERVENTION: Patients were randomized 1:1 to receive either dapagliflozin (10 mg orally; n = 392) or placebo (n = 392) once daily, beginning on the day before surgery and continuing through the second postoperative day.
2. Clinical Obesity Beyond BMI Identifies a Large High-Risk Subgroup in UK Adults.
In 436,751 UK Biobank participants, obesity prevalence increased from 23.92% using BMI alone to 67.58% under a multidimensional framework incorporating adiposity and organ dysfunction. Participants with non-obese BMI but clinical obesity had substantially increased risks of incident type 2 diabetes, nonalcoholic fatty liver disease, chronic kidney failure, heart failure, and thrombosis.
Impact: This study challenges BMI-only classification by quantifying the size and risk of a clinically important subgroup that conventional screening may miss. Its findings are directly relevant to obesity definitions, risk communication, and prevention strategies in endocrinology and primary care.
Clinical Implications: Clinicians may need to assess waist measures, body composition, and obesity-related organ dysfunction rather than relying solely on BMI, particularly in patients with apparently normal or overweight BMI but metabolic or functional abnormalities. However, implementation requires validated thresholds, feasible measurement pathways, and evidence that this classification improves outcomes.
Key Findings
- Obesity prevalence was 23.92% by BMI criteria compared with 67.58% using the new multidimensional criteria.
- Among participants with non-obese BMI but clinical obesity, incident type 2 diabetes risk was increased more than threefold, with a hazard ratio of 3.18.
- The same subgroup had higher risks of nonalcoholic fatty liver disease, chronic kidney failure, heart failure, and thrombosis, with hazard ratios of 2.01, 1.52, 1.37, and 1.36, respectively.
Methodological Strengths
- Very large population-based cohort of 436,751 UK Biobank participants.
- Direct comparison of BMI-based classification with an integrated framework incorporating anthropometry, body composition, and obesity-related organ dysfunction, together with incident outcome analyses.
Limitations
- The UK Biobank population is not fully representative of the general UK population and may have selection and healthy-volunteer biases.
- The observational design cannot establish that the new obesity classification causes better outcomes or that treating newly classified individuals improves health.
- The new framework substantially increases the estimated prevalence of obesity, so its clinical and resource implications require careful validation.
Future Directions: Prospective validation in diverse populations should determine whether multidimensional obesity classification improves prediction, treatment selection, and patient outcomes. Randomized studies should test whether interventions guided by organ dysfunction and body composition outperform BMI-based care.
INTRODUCTION: BMI is widely used to define obesity but does not capture adiposity distribution and related functional impairment. This study assessed obesity prevalence, disease burden, and incident cardiometabolic risk using the new criteria proposed by The Lancet Commission and compared disease burden across BMI-based and functional classifications. METHODS: A population-based cohort study included 436,751 UK Biobank participants cross-classified according to ethnicity-specific BMI thresholds and the new criteria for preclinical and clinical obesity. Obesity was defined using integrated anthropometric and body-composition measures, while clinical obesity was further characterized by obesity-related organ dysfunction. Prevalence, disease burden, incident outcomes, and predictive performance were assessed across obesity categories. Data collected during 2006-2010 and were analyzed in 2026. RESULTS: BMI-defined obesity prevalence was 23.92%, whereas obesity prevalence increased to 67.58% under the new criteria, with clinical obesity accounting for 62.70% of the total population.
3. Multi-ancestry genome-wide association analyses provide insights into the genetic basis of Hashimoto's thyroiditis.
This multi-ancestry genome-wide association meta-analysis included 48,694 Hashimoto's thyroiditis cases and 1,044,134 controls and identified 155 significant genetic loci. The study substantially expands the genetic map of autoimmune hypothyroidism and provides a broader foundation for understanding disease susceptibility across ancestries.
Impact: The exceptionally large, multi-ancestry sample addresses the ancestry limitations of many previous genetic studies and provides a major resource for dissecting autoimmune thyroid disease biology. The findings may support future risk prediction, functional studies, and therapeutic target discovery.
Clinical Implications: The results are not immediately sufficient to change screening or treatment guidelines, but they may eventually improve genetic risk stratification and identify biological pathways relevant to prevention or targeted therapy in Hashimoto's thyroiditis.
Key Findings
- The analysis included 48,694 individuals with Hashimoto's thyroiditis and 1,044,134 controls.
- A total of 155 genome-wide significant loci were identified using a multi-ancestry design.
- The study provides a large-scale genetic framework for investigating autoimmune hypothyroidism beyond predominantly single-ancestry datasets.
Methodological Strengths
- Very large case-control sample with 48,694 cases and more than one million controls.
- Multi-ancestry genome-wide association meta-analysis using a precise disease definition, improving generalizability and phenotype validity.
Limitations
- Genome-wide association findings primarily identify statistical associations and do not by themselves establish causal biological mechanisms.
- The available abstract does not provide detailed information on replication cohorts, functional validation, or the ancestry-specific distribution of the identified loci.
Future Directions: Future work should prioritize independent replication, fine-mapping and functional validation of the 155 loci, assessment of ancestry-specific effects, and integration with transcriptomic, epigenomic, and immune-cell data to identify causal pathways.
Autoimmune hypothyroidism (Hashimoto's thyroiditis) is common and has a strong genetic component. Here we performed multi-ancestry genome-wide association meta-analyses encompassing 48,694 Hashimoto's thyroiditis cases, using a precise case definition, and 1,044,134 controls. We identified 155 significant (P < 5 × 10